NKTR-214: Harnessing the IL-2 Pathway in Combination Immunotherapies
PharmaTalkRadio6 Mars 2020

NKTR-214: Harnessing the IL-2 Pathway in Combination Immunotherapies

In this podcast, first recorded at the 4th annual IO Combinations 360° conference, Dr Willem Overwijk, Nektar Therapeutics discusses Bempegaldesleukin (NKTR-214): harnessing the IL-2 pathway in combination immunotherapies. Topics include: Bempegaldesleukin: Structure and function of an engineered IL-2 cytokine prodrug providing sustained IL-2Rβγ-biased signalingPreclinical PK, PD, MOA and combination with PD-1 checkpoint inhibitionClinical PK, PD, clinical response data and biomarkers in patients with melanoma and bladder cancerCombinations under investigation To learn more about the upcoming IO Combinations 360° conference please visit, www.iocombinations360.com

Det här avsnittet är hämtat från ett öppet RSS-flöde och publiceras inte av Podme. Det kan innehålla reklam.

Avsnitt(461)

Populärt inom Vetenskap

dumma-manniskor
p3-dystopia
allt-du-velat-veta
angestpodden
rss-ronden
rss-ai-med-jonas-benjamin
kapitalet-en-podd-om-ekonomi
rss-kriminologerna
halsorevolutionen
sexet
rss-ufobortom-rimligt-tvivel
det-morka-psyket
bildningspodden
rss-vetenskapsradion-2
medicinvetarna
rss-mottagningen
4health-med-anna-sparre
rss-vetenskapsradion
rss-experimentet
svd-nyhetsartiklar